Literature DB >> 25554429

Ketamine interactions with biomarkers of stress: a randomized placebo-controlled repeated measures resting-state fMRI and PCASL pilot study in healthy men.

Najmeh Khalili-Mahani1, Marieke Niesters2, Matthias J van Osch3, Melly Oitzl4, Ilya Veer5, Mark de Rooij6, Joop van Gerven7, Mark A van Buchem8, Christian F Beckmann9, Serge A R B Rombouts10, Albert Dahan2.   

Abstract

Ketamine, an NMDA receptor antagonist, is increasingly used to study the link between glutamatergic signaling dysregulation and mood and chronic pain disorders. Glutamatergic neurotransmission and stress corticosteroids (cortisol in human) are critical for Ca(2+) mediated neuroplasticity and behavioral adaptation. The mechanisms of action of glutamatergic neurotransmission and stress corticosteroids on the NMDA-receptors of the hippocampus have been long investigated in animals, but given little attention in human studies. In this randomized single-blinded placebo-controlled crossover study (12 healthy young men), five sets of resting-state fMRI (RSFMRI), pseudocontinuous arterial spin labeling (PCASL), and corresponding salivary cortisol samples were acquired over 4h, at given intervals under pharmacokinetically-controlled infusion of subanesthetic ketamine (20 & 40mg/70kg/h). An identical procedure was repeated under a sham placebo condition. Differences in the profile of ketamine versus placebo effect over time were examined. Compared to placebo, ketamine mimicked a stress-like response (increased cortisol, reduced calmness and alertness, and impaired working memory). Ketamine effects on the brain included a transient prefrontal hyperperfusion and a dose-related reduction of relative hippocampal perfusion, plus emerging hyperconnectivity between the hippocampus and the occipital, cingulate, precuneal, cerebellar and basal ganglia regions. The spatiotemporal profiles of ketamine effects on different hippocampal subnetworks suggest a topographically dissociable change in corticohippocampal functional connectivity. We discuss our findings in the context of the negative feedback inhibition theory of the hippocampal stress-control. This pilot study provides a methodological framework for multimodal functional neuroimaging under resting-state conditions, which may be generalized for translational studies of glutamatergic- or stress-related etiology of neuropsychiatric disorders.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25554429     DOI: 10.1016/j.neuroimage.2014.12.050

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  22 in total

1.  Modulatory effects of ketamine, risperidone and lamotrigine on resting brain perfusion in healthy human subjects.

Authors:  Sergey Shcherbinin; Orla Doyle; Fernando O Zelaya; Sara de Simoni; Mitul A Mehta; Adam J Schwarz
Journal:  Psychopharmacology (Berl)       Date:  2015-07-31       Impact factor: 4.530

2.  Ketamine administration reduces amygdalo-hippocampal reactivity to emotional stimulation.

Authors:  Milan Scheidegger; Anke Henning; Martin Walter; Mick Lehmann; Rainer Kraehenmann; Heinz Boeker; Erich Seifritz; Simone Grimm
Journal:  Hum Brain Mapp       Date:  2016-02-25       Impact factor: 5.038

Review 3.  Biomarkers, designs, and interpretations of resting-state fMRI in translational pharmacological research: A review of state-of-the-Art, challenges, and opportunities for studying brain chemistry.

Authors:  Najmeh Khalili-Mahani; Serge A R B Rombouts; Matthias J P van Osch; Eugene P Duff; Felix Carbonell; Lisa D Nickerson; Lino Becerra; Albert Dahan; Alan C Evans; Jean-Paul Soucy; Richard Wise; Alex P Zijdenbos; Joop M van Gerven
Journal:  Hum Brain Mapp       Date:  2017-02-01       Impact factor: 5.038

4.  Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats.

Authors:  Oliver Grimm; Natalia Gass; Wolfgang Weber-Fahr; Alexander Sartorius; Esther Schenker; Michael Spedding; Celine Risterucci; Janina Isabel Schweiger; Andreas Böhringer; Zhenxiang Zang; Heike Tost; Adam James Schwarz; Andreas Meyer-Lindenberg
Journal:  Psychopharmacology (Berl)       Date:  2015-07-18       Impact factor: 4.530

Review 5.  Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature.

Authors:  Dawn F Ionescu; Julia M Felicione; Aishwarya Gosai; Cristina Cusin; Philip Shin; Benjamin G Shapero; Thilo Deckersbach
Journal:  Harv Rev Psychiatry       Date:  2018 Nov/Dec       Impact factor: 3.732

6.  Ketamine-induced changes in connectivity of functional brain networks in awake female nonhuman primates: a translational functional imaging model.

Authors:  Kaundinya Gopinath; Eric Maltbie; Naoko Urushino; Doty Kempf; Leonard Howell
Journal:  Psychopharmacology (Berl)       Date:  2016-08-16       Impact factor: 4.530

7.  Corticoadrenal and Cardiorespiratory Responses to Administration of Propofol Combined with Dexmedetomidine or Ketamine in Rabbits.

Authors:  Alfredo González-Gil; Rosa Ana Picazo; Paul de Bruyn; Juan Carlos Illera
Journal:  J Am Assoc Lab Anim Sci       Date:  2018-05-01       Impact factor: 1.232

8.  Preliminary differences in resting state MEG functional connectivity pre- and post-ketamine in major depressive disorder.

Authors:  Allison C Nugent; Stephen E Robinson; Richard Coppola; Carlos A Zarate
Journal:  Psychiatry Res Neuroimaging       Date:  2016-06-23       Impact factor: 2.376

9.  Depression in chronic ketamine users: Sex differences and neural bases.

Authors:  Chiang-Shan R Li; Sheng Zhang; Chia-Chun Hung; Chun-Ming Chen; Jeng-Ren Duann; Ching-Po Lin; Tony Szu-Hsien Lee
Journal:  Psychiatry Res Neuroimaging       Date:  2017-09-05       Impact factor: 2.376

Review 10.  The role of fMRI in drug development.

Authors:  Owen Carmichael; Adam J Schwarz; Christopher H Chatham; David Scott; Jessica A Turner; Jaymin Upadhyay; Alexandre Coimbra; James A Goodman; Richard Baumgartner; Brett A English; John W Apolzan; Preetham Shankapal; Keely R Hawkins
Journal:  Drug Discov Today       Date:  2017-11-15       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.